Drug intelligence / Profile preview

alisvetcel

Development stage: Unknown
Lead developer: Global Stem cell Technology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

**Alisvetcel** is an allogeneic, peripheral blood-derived equine mesenchymal stem-cell therapy that is chondrogenically induced before administration. Marketed as **Arti-Cell Forte**, it is an intra-articular veterinary biologic for horses, authorized to reduce mild-to-moderate recurrent lameness associated with non-septic joint inflammation. The cells are intended to support cartilage repair and restoration of joint health through regenerative cell-therapy activity rather than a single defined receptor target. ([boehringer-ingelheim.com](https://www.boehringer-ingelheim.com/animal-health/products/arti-cell-forte))

Brand names: Arti-Cell Forte
Other names: chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells

Beyond the preview

Go deeper on alisvetcel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alisvetcel.

Explore the full profile